CoChat

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

The DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index.

Abstract

Background Individuals with diabetes are at increased risk of cardiovascular morbidity and mortality, although typically their plasma concentrations of LDL cholesterol are similar to those in the general population. Previous evidence about the effects of lowering cholesterol in people with diabetes has been limited, and most diabetic patients do not currently receive cholesterol-lowering therapy despite their increased risk. Methods 5963 UK adults (aged 40-80 years) known to have diabetes, and an additional 14573 with occlusive arterial disease (but no diagnosed diabetes), were randomly allocated to receive 40 mg simvastatin daily or matching placebo. Prespecified analyses in these prior disease subcategories, and other relevant subcategories, were of first major coronary event (ie, non-fatal myocardial infarction or coronary death) and of first major vascular event (ie, major coronary event, stroke or revascularisation). Analyses were also conducted of subsequent vascular events during the scheduled treatment period. Comparisons are of all simvastatin-allocated versus all placebo-allocated participants (ie, intention to treat), which yielded an average difference in LDL cholesterol of 1.0 mmol/L (39 mg/dL) during the 5-year treatment period. Findings Both among the participants who presented with diabetes and among those who did not, there were highly significant reductions of about a quarter in the first event rate for major coronary events, for strokes, and for revasculari…

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(03)13636-7

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

15 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 51 references

Cited by

See all 2,876

Metadata

Authors
Collins, R., Armitage, J., Parish, S., Sleigh, P., & Peto, R.
Venue
The Lancet
Publisher
Elsevier BV
Published
2003-06
Volume
361
Issue
9374
Pages
2005-2016
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W1502524639
Cited by
2,876
References
52
Citations by year
2026: 18 · 2025: 16 · 2024: 45 · 2023: 55 · 2022: 39 · 2021: 36 · 2020: 66 · 2019: 81 · 2018: 72 · 2017: 63 · 2016: 94 · 2015: 110 · 2014: 157 · 2013: 156 · 2012: 147
FWCI
244.81
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords
simvastatin, diabetes mellitus, cholesterol-lowering therapy, LDL cholesterol, cardiovascular events, major coronary events, stroke, revascularization, arterial occlusive disease, cardiovascular risk reduction, statins, primary prevention, cardiovascular morbidity, myocardial infarction prevention
MeSH terms
Adult, Aged, Aged, 80 and over, Alanine Transaminase, Anticholesteremic Agents, Cardiovascular Diseases, Creatine Kinase, Creatinine, Diabetes Mellitus, Female, Humans, Lipids, Male, Middle Aged, Myocardial Revascularization, Patient Compliance, Placebos, Prospective Studies, Risk Factors, Treatment Outcome, Simvastatin, Diabetes Complications

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(03)13636-7
The paper
Collins, R., Armitage, J., Parish, S., Sleigh, P., & Peto, R. (2003). MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(03)13636-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.